Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulforaphane is a naturally occurring isothiocyanate compound found in cruciferous vegetables such as broccoli, Brussels sprouts, and cabbage. It is produced when the enzyme myrosinase converts glucoraphanin (a glucosinolate precursor) into sulforaphane upon plant tissue damage (e.g., chewing or chopping)[3][1][6]. Sulforaphane exists as two stereoisomers; the R-enantiomer occurs naturally, while the S-enantiomer can be synthesized[3][1]. It acts primarily as an inducer of phase II detoxification enzymes via activation of the NRF2 signaling pathway and displays antioxidant, anticarcinogenic, antidiabetic, and antimicrobial properties in experimental models[8][6][7]. Despite promising preclinical data on cancer prevention and other health benefits, there is no conclusive clinical evidence supporting its efficacy for disease prevention or treatment as of 2025[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulforaphane.